J D Woolley1, B Chuang1, C Fussell1, S Scherer2, B Biagianti3, D Fulford4, D H Mathalon1, S Vinogradov1. 1. Department of Psychiatry,San Francisco Veterans Affairs Medical Center,San Francisco,CA,USA. 2. Institute for Creative Technologies,University of Southern California,Los Angeles,CA,USA. 3. Department of Psychiatry,University of California San Francisco,San Francisco,CA,USA. 4. Departments of Occupational Therapy and Psychological & Brain Sciences,Boston University,Boston,MA,USA.
Abstract
BACKGROUND: Blunted facial affect is a common negative symptom of schizophrenia. Additionally, assessing the trustworthiness of faces is a social cognitive ability that is impaired in schizophrenia. Currently available pharmacological agents are ineffective at improving either of these symptoms, despite their clinical significance. The hypothalamic neuropeptide oxytocin has multiple prosocial effects when administered intranasally to healthy individuals and shows promise in decreasing negative symptoms and enhancing social cognition in schizophrenia. Although two small studies have investigated oxytocin's effects on ratings of facial trustworthiness in schizophrenia, its effects on facial expressivity have not been investigated in any population. METHOD: We investigated the effects of oxytocin on facial emotional expressivity while participants performed a facial trustworthiness rating task in 33 individuals with schizophrenia and 35 age-matched healthy controls using a double-blind, placebo-controlled, cross-over design. Participants rated the trustworthiness of presented faces interspersed with emotionally evocative photographs while being video-recorded. Participants' facial expressivity in these videos was quantified by blind raters using a well-validated manualized approach (i.e. the Facial Expression Coding System; FACES). RESULTS: While oxytocin administration did not affect ratings of facial trustworthiness, it significantly increased facial expressivity in individuals with schizophrenia (Z = -2.33, p = 0.02) and at trend level in healthy controls (Z = -1.87, p = 0.06). CONCLUSIONS: These results demonstrate that oxytocin administration can increase facial expressivity in response to emotional stimuli and suggest that oxytocin may have the potential to serve as a treatment for blunted facial affect in schizophrenia.
RCT Entities:
BACKGROUND: Blunted facial affect is a common negative symptom of schizophrenia. Additionally, assessing the trustworthiness of faces is a social cognitive ability that is impaired in schizophrenia. Currently available pharmacological agents are ineffective at improving either of these symptoms, despite their clinical significance. The hypothalamic neuropeptideoxytocin has multiple prosocial effects when administered intranasally to healthy individuals and shows promise in decreasing negative symptoms and enhancing social cognition in schizophrenia. Although two small studies have investigated oxytocin's effects on ratings of facial trustworthiness in schizophrenia, its effects on facial expressivity have not been investigated in any population. METHOD: We investigated the effects of oxytocin on facial emotional expressivity while participants performed a facial trustworthiness rating task in 33 individuals with schizophrenia and 35 age-matched healthy controls using a double-blind, placebo-controlled, cross-over design. Participants rated the trustworthiness of presented faces interspersed with emotionally evocative photographs while being video-recorded. Participants' facial expressivity in these videos was quantified by blind raters using a well-validated manualized approach (i.e. the Facial Expression Coding System; FACES). RESULTS: While oxytocin administration did not affect ratings of facial trustworthiness, it significantly increased facial expressivity in individuals with schizophrenia (Z = -2.33, p = 0.02) and at trend level in healthy controls (Z = -1.87, p = 0.06). CONCLUSIONS: These results demonstrate that oxytocin administration can increase facial expressivity in response to emotional stimuli and suggest that oxytocin may have the potential to serve as a treatment for blunted facial affect in schizophrenia.
Entities:
Keywords:
Blunted affect; facial expressivity; oxytocin; schizophrenia; social cognition; trustworthiness
Authors: Ellen R Bradley; Alison Seitz; Andrea N Niles; Katherine P Rankin; Daniel H Mathalon; Aoife O'Donovan; Joshua D Woolley Journal: Schizophr Res Date: 2019-08-12 Impact factor: 4.939
Authors: Samantha V Abram; Lize De Coster; Brian J Roach; Bryon A Mueller; Theo G M van Erp; Vince D Calhoun; Adrian Preda; Kelvin O Lim; Jessica A Turner; Judith M Ford; Daniel H Mathalon; Joshua D Woolley Journal: Schizophr Bull Date: 2020-04-10 Impact factor: 9.306
Authors: Marta Broniarczyk-Czarniak; Janusz Szemraj; Janusz Śmigielski; Piotr Gałecki Journal: Curr Issues Mol Biol Date: 2022-01-12 Impact factor: 2.976
Authors: Elissar Andari; Nicholas M Massa; Molly D Fargotstein; Nicholas B Taylor; David M Halverson; Andrew V Owens; Danielle L Currin; Arpita Bhattacharya; Dmitriy Gitman; Bruce C Cuthbert; Larry J Young; Erica J Duncan Journal: J Clin Psychopharmacol Date: 2021 Mar-Apr 01 Impact factor: 3.153
Authors: Katherine R Thorson; Scott M McKernan; Tessa V West; Joshua D Woolley; Wendy Berry Mendes; Christopher S Stauffer Journal: Sci Rep Date: 2021-10-25 Impact factor: 4.379